Le Lézard
Classified in: Health, Business
Subjects: NPT, PER

HealthWell Foundation Initiates Nationwide Search for Next President & CEO


GERMANTOWN, Md., April 17, 2024 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans is pleased to announce that it has initiated a nationwide search for its next President & Chief Executive Officer.

The HealthWell Foundation is seeking an innovative and visionary leader who can promote program development and sustainable growth. The President/CEO must be capable of maintaining a compliant, ethical organization and possess strong financial acumen. The successful candidate will be a creative leader who recognizes that our commitment to compliance and the highest ethical standards are the cornerstone of our operations. This position is a critical component in ensuring that the Foundation continues to compliantly carry out its mission to reduce financial barriers to care for underinsured patients with chronic or life-altering diseases.

The successful candidate will be an effective organizational strategist with a history of accomplishing complex goals and maintaining positive relationships with the board, direct reports, staff, donors, partners, and other stakeholders. 

"For more than two decades, the HealthWell Foundation has served as a financial lifeline for more than 930,000 underinsured Americans who would otherwise have forgone critical, often lifesaving, medical treatments, simply because their health insurance was inadequate," said David L. Knowlton, HealthWell Foundation Board Chair. "The Foundation is poised for continued growth and selecting a candidate with the qualities and skills to lead us into the next decade is paramount to our ability to execute on our mission to serve those in need."

To learn more and apply for the President & Chief Executive Officer position, visit the Career Opportunities section of our website at https://www.healthwellfoundation.org/career-opportunities/. To learn more about HealthWell programs and our robust disease fund portfolio, visit HealthWellFoundation.org.

About the HealthWell Foundation
A nationally recognized, independent non-profit organization founded in 2003 and a resource to the White House Cancer Moonshot Initiative, the HealthWell Foundation has served as a safety net across over 90 disease areas for more than 930,000 underinsured patients. Since its inception, HealthWell has provided over $4 billion in financial support through more than 1.5 million grants to access life-changing medical treatments patients otherwise would not be able to afford. HealthWell provides financial assistance to adults and children facing medical hardship resulting from gaps in their insurance that cause out-of-pocket medical expenses to escalate rapidly; HealthWell assists with the treatment-related cost-sharing obligations of these patients. HealthWell ranked 23rd on the 2023 Forbes list of America's Top 100 Charities and was recognized for its 100 percent fundraising efficiency. For more information, visit HealthWellFoundation.org.

CONTACT:
Ginny Dunn
240-632-5309
[email protected]

SOURCE HealthWell Foundation


These press releases may also interest you

at 04:52
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled,...

at 04:09
A news report from China Daily: The 2024 ZGC Forum in Beijing showcased a wide range of latest technological innovations. The event ran from April 25 to 29 and comprised 128 activities, including forums and conferences, technology exchanges,...

at 04:05
Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , disclosed today that under the...

at 03:38
Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January ? March...

at 03:05
The European Academy of Allergy and Clinical...

at 03:00
BioWorldtm published by  Clarivate Plc , a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report...



News published on and distributed by: